uniQure Selected as Fierce 15 Company by FierceBiotech

uniQure Selected as Fierce 15 Company by FierceBiotech

AMSTERDAM, the Netherlands, Sep 24, 2013 (GLOBE NEWSWIRE via COMTEX) -- uniQure B.V. has been named by FierceBiotech as one of 2013's Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual Fierce 15 selection.

"Once a barren wasteland of broken dreams, the gene therapy field has come alive in recent years with the help of companies like uniQure," says FierceBiotech Editor John Carroll. "There are plenty of challenges ahead, but the approval in the European Union of uniQure's Glybera, the first gene therapy drug approved in the Western world, and other recent achievements bode well for the company's future."

"Joining the ranks of Fierce 15 companies is an honor and welcome recognition of all the hard work by our dedicated employees," adds Jorn Aldag, CEO of uniQure. "Our goals remain to advance our pipeline of treatments toward commercialization and to expand the potential of gene therapy."

The Fierce 15 celebrates the spirit of being "fierce" - championing innovation and creativity, even in the face of intense competition.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

A complete list of "Fierce 15" companies, the online newsletter's eleventh annual selection, is available online at FierceBiotech.com.

About uniQure

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera in the European Union. www.uniqure.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 100,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signing up is free.

Press release (PDF): http://hugin.info/157414/R/1730784/578652.pdf

        CONTACT: Jorn Aldag
                 CEO uniQure
                 T: +31 20 566 8014
                 [email protected]
                 Media inquiries:
                 MacDougall Biomedical Communications
                 Doug MacDougall (US)
                 +1 781 235 3060
                 [email protected]
                 Gretchen Schweitzer (Europe)
                 +49 172 861 8540
                 [email protected]

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.